Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy
Michal Herman‐Edelstein(Rabin Medical Center), Uzi Gafter(Tel Aviv University)
Cited by 627
Related Papers
Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial
|The Lancet|2000|1k
SGLT2 Protein Expression Is Increased in Human Diabetic Nephropathy
|Journal of Biological Chemistry|2017|302
FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity
|Journal of the American Society of Nephrology|2017|222
G Protein-Coupled Bile Acid Receptor TGR5 Activation Inhibits Kidney Disease in Obesity and Diabetes
|Journal of the American Society of Nephrology|2015|208